Palo Alto VA Tests Feasibility of Liquid Biopsy as Lung Cancer Screening Tool
The VA Palo Alto Health Care System stepped up to be the first testing site for an early detection study in lung cancer that uses a blood assay as a screening mechanism.
The VA Palo Alto Health Care System stepped up to be the first testing site for an early detection study in lung cancer that uses a blood assay as a screening mechanism.
The most common form of cancer, nonmelanoma skin cancer (NMSC) — composed primarily of basal cell carcinoma and squamous cell carcinoma — affects about 3.3 million people annually.
Since the 1990s, both melanoma and nonmelanoma skin cancer have become more prevalent in the United States. Across the nation, more than 9,500 people are diagnosed with skin cancer every day.
From the time the COVID-19 mRNA vaccines became available in late 2020, VA studies have been crucial to understanding their effectiveness in real life.
The latter half of December and the first weeks of the new year were trying times for hospitals as the Omicron variant began sweeping across the country, causing infection rates and hospitalizations to rise to levels unprecedented even during the earliest months of the pandemic.